Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gilead Sciences's EBITDA for the
three
months ended in Jun. 2026 was MXN-162,433 Mil. Gilead Sciences's Revenue for the
three
months ended in Jun. 2026 was MXN136,155 Mil. Therefore, Gilead Sciences's EBITDA margin for the quarter that ended in Jun. 2026 was -119.30%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gilead Sciences EBITDA Margin % Related Terms
Gilead Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GILD vs PFE, BMY, AMGN: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (MEX:GILD) has a EBITDA Margin % of -119.30% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gilead Sciences and its competitors. Over the past decade, Gilead Sciences' EBITDA Margin % has ranged from 5.92 to 63.24. According to the industry distribution chart, Gilead Sciences ranks #706 out of 960 companies in the Drug Manufacturers industry, placing it in the top 73.5%.
Is Gilead Sciences' EBITDA Margin % too high?
Gilead Sciences' current EBITDA Margin % is -119.30%. Over the past 10 years, this metric has ranged from a low of 5.92 to a high of 63.24. Based on the distribution chart, Gilead Sciences ranks #706 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gilead Sciences has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' EBITDA Margin % compare to PFE and BMY?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #706 out of 960 companies for EBITDA Margin %. This places Gilead Sciences in the lower half of its industry. The industry median EBITDA Margin % is 12.16. Historically, Gilead Sciences' own EBITDA Margin % has ranged from 5.92 to 63.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current EBITDA Margin % is -119.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (MEX:GILD) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,812.75, compared to a current price of MXN2,300.00 — trading 26.9% above its estimated fair value. The current EBITDA Margin % is -119.30%. Gilead Sciences' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gilead Sciences (MEX:GILD), the current EBITDA Margin % is -119.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (MEX:GILD) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of MXN2,300.00 is trading 26.9% above its estimated GF Value™ of MXN1,812.75.
GuruFocus considers Gilead Sciences to be Modestly Overvalued.
Key valuation signals for MEX:GILD:
EBITDA Margin %: -119.30%
GF Value™: MXN1,812.75 vs. price of MXN2,300.00 (26.9% above fair value)
No single metric tells the full story. See the MEX:GILD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
68GF Score
Get the complete analysis for MEX:GILD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GILD has been successfully added to your 
